Merck Eprova and Isofol Medical Enter Exclusive Agreement for Merck Eprova's Modufolin in oncology
12-Nov-2009 -
Merck Eprova AG announced that the company has signed an exclusive license agreement with Isofol Medical AB of Sweden to utilize Merck Eprova’s proprietary folate compound Modufolin® in oncology. The use of Modufolin® is expected to enhance effectiveness compared to currently used folate ...
clinical trials
DNA replication
inhibitors
+6